Biohaven
BHVN
52 hedge funds and large institutions have $535M invested in Biohaven in 2022 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.63% more ownership
Funds ownership: 0% → 13.63% (+14%)
69% less call options, than puts
Call options by funds: $20.7M | Put options by funds: $67.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$10.6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$9.56M |
| 3 |
Millennium Management
New York
|
+$7.51M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$7.44M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.68M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIC
51
SJS Investment Consulting
Sylvania,
Ohio
| – | +$29 | +4 | New |
|
52
State Street
Boston,
Massachusetts
| – | +$3.49M | +480,337 | New |
|
BHVN Hedge Fund Activity: Q3 2022 in Review
52 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Biohaven (BHVN) for Q3 2022, worth a combined $535M.
Buyers outnumbered sellers: 52 funds opened new BHVN positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $10.6M.
- 52 institutional investors held Biohaven (BHVN) as of Q3 2022, up from 0 in Q2 2022.
- Funds reported $535M of Biohaven stock for Q3 2022.
- 52 funds opened new Biohaven positions in Q3 2022 and 0 closed out, a net change of +52 holders.
- The largest Biohaven buyer in Q3 2022 was Armistice Capital, an estimated $10.6M added.
Based on aggregated 13F filings for Q3 2022.